Nuvation Bio (NYSE: NUVB) insider transactions
In the twelve months to 10 November 2026, executives and directors of Nuvation Bio reported 16 open-market sales of 1,411,469 shares ($9.2m) and 1 open-market purchase of 25,000 shares ($118,250), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 August 2026 | Hattersley Gary | Chief Scientific Officer | Option exercise, 10b5-1 plan | +100,000 | $1.87 | 100,000 | Form 4 |
| 19 August 2026 | Hattersley Gary | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −100,000 | $7.09 | 0 | Form 4 |
| 15 July 2026 | Sauvage Philippe | Chief Financial Officer | Option exercise | +39,999 | $2.17 | 54,130 | Form 4 |
| 15 July 2026 | Sauvage Philippe | Chief Financial Officer | Option exercise | +1 | $1.97 | 54,131 | Form 4 |
| 23 June 2026 | Wentworth Kerry | Chief Regulatory Officer | Option exercise, 10b5-1 plan | +63,000 | $2.93 | 116,000 | Form 4 |
| 23 June 2026 | Wentworth Kerry | Chief Regulatory Officer | Open-market sale, 10b5-1 plan | −63,000 | $6.02 | 53,000 | Form 4 |
| 23 June 2026 | Markel Stacy | Chief People Officer | Option exercise, 10b5-1 plan | +90,380 | $1.87 | 122,971 | Form 4 |
| 23 June 2026 | Markel Stacy | Chief People Officer | Option exercise, 10b5-1 plan | +34,620 | $1.74 | 157,591 | Form 4 |
| 23 June 2026 | Markel Stacy | Chief People Officer | Open-market sale, 10b5-1 plan | −125,000 | $6.03 | 32,591 | Form 4 |
| 23 June 2026 | Sauvage Philippe | Chief Financial Officer | Option exercise, 10b5-1 plan | +47,668 | $2.17 | 60,341 | Form 4 |
| 23 June 2026 | Sauvage Philippe | Chief Financial Officer | Open-market sale, 10b5-1 plan | −47,668 | $6.01 | 12,673 | Form 4 |
| 9 June 2026 | Mashal Robert | Director | Open-market purchase | +25,000 | $4.73 | 225,000 | Form 4 |
| 17 April 2026 | Wentworth Kerry | Chief Regulatory Officer | Option exercise, 10b5-1 plan | +36,750 | $2.93 | 89,750 | Form 4 |
| 17 April 2026 | Wentworth Kerry | Chief Regulatory Officer | Open-market sale, 10b5-1 plan | −36,750 | $5.01 | 53,000 | Form 4 |
| 17 April 2026 | Liu Dongfang | Chief Medical Officer | Option exercise, 10b5-1 plan | +50,000 | $1.94 | 68,000 | Form 4 |
| 17 April 2026 | Liu Dongfang | Chief Medical Officer | Open-market sale, 10b5-1 plan | −50,000 | $5.02 | 18,000 | Form 4 |
| 6 April 2026 | Wentworth Kerry | Chief Regulatory Officer | Option exercise, 10b5-1 plan | +100,000 | $1.87 | 153,000 | Form 4 |
| 6 April 2026 | Wentworth Kerry | Chief Regulatory Officer | Option exercise, 10b5-1 plan | +100,000 | $1.94 | 253,000 | Form 4 |
| 6 April 2026 | Wentworth Kerry | Chief Regulatory Officer | Open-market sale, 10b5-1 plan | −200,000 | $4.52 | 53,000 | Form 4 |
| 27 February 2026 | Makunje Moses | See Remarks | Grant or award | +50,761 | — | 68,137 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Nuvation Bio page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.